Dec 09, 2019 8:30am EST Emerald Bioscience Reports its Proprietary Analog of Cannabidiol, Cannabidiol-Valine-Hemisuccinate (CBDVHS), Exhibits Greater Potency and Antifibrotic Activity than Cannabidiol (CBD) in Biomarker Studies in Human Ocular Donor Tissues
Oct 30, 2019 8:30am EDT Emerald Bioscience to Present Research Data Related to its Glaucoma Drug Candidate, NB1111, at 2019 American Association of Pharmaceutical Scientists
Oct 15, 2019 8:35am EDT Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model
Oct 15, 2019 8:30am EDT Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma
Oct 03, 2019 8:30am EDT Glauconix Biosciences and University of Mississippi to Present Research Data Related to Emerald Bioscience’s Glaucoma Drug Candidate, NB1111, at 2019 American Academy of Ophthalmology Annual Meeting
Aug 27, 2019 8:30am EDT Emerald Bioscience to Participate in Investment and Scientific Conferences in September
Aug 26, 2019 8:30am EDT Emerald Bioscience Appoints Chief Medical Officer and Executive Director, Clinical Operations
Aug 13, 2019 8:30am EDT Emerald Bioscience Starts Australian Operation Ahead of Planned Glaucoma Study
